The center will deploy PathAI’s AISight Dx platform across its pathology programs to enhance diagnostic accuracy, support research, and advance AI integration in cancer care.
PathAI and Moffitt Cancer Center announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight Dx, across Moffitt’s pathology programs to advance cancer detection and AI diagnostics.
The partnership establishes a framework for joint research programs, real-world multimodal data collection, clinical trial support, biopharma collaborations, and co-development of AI-based diagnostics for precision medicine applications.
AISight Dx is PathAI’s cloud-native digital pathology image management system designed to support laboratory workflow and translational research use cases. The platform combines enterprise-scale slide management, viewing, and collaboration with AI integration to drive pathology operational efficiencies and enhanced speed and accuracy.
“We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,” says Andy Beck, MD, PhD, CEO and co-founder of PathAI, in a release. “By deploying AISight Dx and building this strategic partnership, we’re equipping Moffitt’s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.”
Digital Pathology Integration for Clinical Oncology
The collaboration aligns with Moffitt’s mission to contribute to cancer prevention and cure through care, science and innovation. The deployment of AISight Dx into Moffitt’s pathology infrastructure represents integration of AI-driven technology into clinical oncology to enable faster, more accurate pathologist review.
“This collaboration aligns perfectly with Moffitt’s mission to contribute to the prevention and cure of cancer through care, cutting-edge science and innovation,” says Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center, in a release. “By deploying AISight Dx into our pathology infrastructure, we’re taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review.”
The partnership aims to drive Moffitt’s digital change by unlocking pathology data and integrating it with imaging and clinical insights to deliver personalized patient care.
“Adopting cutting-edge digital pathology technologies is key to driving Moffitt’s vision for a true digital change, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,” says William Westra, MD, vice chair of pathology at Moffitt Cancer Center, in a release. “By partnering with PathAI, we’re laying the groundwork for next-generation oncology research that will shape future AI-powered care models.”
Regulatory Status and Market Position
AISight Dx is FDA-cleared for primary diagnosis in the US and is CE-IVD-marked for primary diagnosis in the European Economic Area, UK, and Switzerland. The research-use-only version, AISight, is available for research applications in the US.
PathAI positions itself as a leading provider of integrated AI and digital pathology solutions focused on workflow and operational efficiency in pathology labs worldwide. The company aims to enhance patient outcomes and drive the future of medical diagnostics through innovative technologies and strategic partnerships.
The collaboration between PathAI and Moffitt Cancer Center aims to redefine the role of digital pathology and AI in cancer care, setting a precedent for how technologies and clinical expertise can converge to drive improvements in pathology.
ID 367916523 © Yuri Arcurs | Dreamstime.com
